TNXP - Tonix Pharmaceuticals Holding Corp.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
4.15
-0.04 (-0.95%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close4.19
Open4.16
Bid4.01 x 2000
Ask4.68 x 5000
Day's Range4.00 - 4.22
52 Week Range2.70 - 5.11
Volume125,456
Avg. Volume119,073
Market Cap35.112M
Beta2.85
PE Ratio (TTM)N/A
EPS (TTM)-3.01
Earnings DateMay 14, 2018 - May 18, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est9.40
Trade prices are not sourced from all markets
  • ACCESSWIRE5 days ago

    Today's Research Reports on Trending Tickers: CRISPR Therapeutics and Tonix Pharmaceuticals

    NEW YORK, NY / ACCESSWIRE / July 17, 2018 / U.S. markets closed mostly lower on Monday, as upbeat economic data and the latest batch of corporate earnings failed to encourage investors. The Dow Jones Industrial ...

  • Why Tonix Pharmaceuticals Stock Soared Today
    Market Realist5 days ago

    Why Tonix Pharmaceuticals Stock Soared Today

    Today, Tonix Pharmaceuticals (TNXP) was trading at $4.23, which represents ~7.09% growth from yesterday’s close of $3.95.

  • Benzinga5 days ago

    Tonix Shares Surge On Fast Struck Status For Alzheimer's-Related Agitation Candidate

    Tonix Pharmaceuticals Holding Corp (NASDAQ: TNXP ) shares are surging higher on roughly 25 times their average volume after the biotech's pipeline candidate was granted  fast track designation by the Food ...

  • Benzinga6 days ago

    Benzinga Pro's 5 Stocks To Watch Today

    Each day, the Benzinga Pro news team highlights several stocks with Trading Idea potential. Be the first to see them by becoming a Benzinga Pro user ! Coda Octopus Group, Inc. (NASDAQ: CODA ) stock soared ...

  • GlobeNewswire6 days ago

    Tonix Pharmaceuticals Receives Fast Track Designation from the U.S. FDA for TNX-102 SL for Treatment of Agitation in Alzheimer’s Disease

    Tonix Pharmaceuticals Holding Corp. (TNXP) (Tonix), today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to its investigational new drug, TNX-102 SL, for the treatment of agitation in Alzheimer’s disease. The same drug, TNX-102 SL, or Tonmya®*, for the treatment of posttraumatic stress disorder (PTSD), has previously been designated as a Breakthrough Therapy by the FDA.  It is currently in a Phase 3 study for military-related PTSD, with an interim analysis expected in the third quarter of 2018.

  • Bullish Insiders Bought More Of These Stocks In June
    Simply Wall St.last month

    Bullish Insiders Bought More Of These Stocks In June

    Generally, insiders buying more shares in their own firm sends a bullish signal. A research published in The MIT Press (1998) concluded that stocks following insider buying outperformed the marketRead More...

  • GlobeNewswire2 months ago

    Tonix Pharmaceuticals Presented New Data Related to Suicidal Ideation and Behaviors in Military-Related PTSD from the Phase 2 AtEase Study at the American Society of Clinical Psychopharmacology

    Tonix Pharmaceuticals Holding Corp. (TNXP) (Tonix), presented data from the Phase 2 AtEase study of Tonmya®* (cyclobenzaprine HCl sublingual tablets) for the treatment posttraumatic stress disorder (PTSD).  “There are several examples in major psychiatric disorders in which pharmacological treatment of the underlying disorder may decrease suicidal behaviors,” said Gregory Sullivan, M.D., Chief Medical Officer of Tonix.

  • GlobeNewswire2 months ago

    Tonix Pharmaceuticals to Present at the 2018 BIO International Convention

    NEW YORK, May 30, 2018-- Tonix Pharmaceuticals Holding Corp., announced today that Seth Lederman, M.D., President and Chief Executive Officer of Tonix, will present an overview of the Company, focusing ...

  • GlobeNewswire2 months ago

    Tonix Pharmaceuticals Reports Preliminary Results from a Phase 1 Pivotal Multiple-Dose Bridging Pharmacokinetic (PK) Study of Tonmya® or TNX-102 SL

    Tonix Pharmaceuticals Holding Corp. (TNXP) (Tonix), announced preliminary results from a Phase 1 pivotal multiple-dose bridging pharmacokinetic study of Tonmya®*, or TNX-102 SL, which is required to support the 505(b)(2) NDA submission for TNX-102 SL, using AMRIX®#  (cyclobenzaprine HCl extended-release [ER]) capsules) as the reference listed drug (RLD).  The design of this study had been previously accepted by the FDA. Specifically, the study compared the plasma levels and the safety profile of TNX-102 SL 5.6 mg (administered as 2 x 2.8 mg tablets) taken sublingually versus the recommended dose of the RLD, AMRIX 30 mg ER capsule, over 20 consecutive days of daily dosing under fasting conditions in healthy subjects aged 18-65 years old.  Tonmya is in Phase 3 development for the bedtime treatment of military-related posttraumatic stress disorder (PTSD) and TNX-102 SL has an effective IND for a Phase 2 efficacy study for the treatment of agitation in Alzheimer’s disease.

  • GlobeNewswire2 months ago

    Tonix Pharmaceuticals to Present at the 2018 American Society of Clinical Psychopharmacology

    NEW YORK, May 23, 2018-- Tonix Pharmaceuticals Holding Corp. announced today that Gregory Sullivan, M.D., Chief Medical Officer of Tonix, will present at the 2018 American Society of Clinical Psychopharmacology ...

  • Associated Press2 months ago

    Tonix: 1Q Earnings Snapshot

    The New York-based company said it had a loss of 88 cents per share. The results missed Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research was for a ...

  • GlobeNewswire2 months ago

    Tonix Pharmaceuticals Reports First Quarter 2018 Financial Results and Provides Programs Update

    Interim Analysis for Phase 3 HONOR study of Tonmya ® in Military-Related PTSD Expected in Third Quarter of 2018. NEW YORK, May 14, 2018-- Tonix Pharmaceuticals Holding Corp., a clinical-stage biopharmaceutical ...

  • GlobeNewswire2 months ago

    Tonix Pharmaceuticals to Present at the BIO KOREA 2018 International Convention

    NEW YORK, May 07, 2018-- Tonix Pharmaceuticals Holding Corp., a clinical-stage biopharmaceutical company focused on developing pharmaceutical products to treat serious neuropsychiatric conditions and biological ...

  • Benzinga3 months ago

    Benzinga Pro's 5 Stocks To Watch Today

    Each day, the Benzinga Pro news team highlights several stocks with Trading Idea potential. Be the first to see them by becoming a Benzinga Pro user ! Heat Biologics Inc (NASDAQ: HTBX ) stock was trading ...

  • GlobeNewswire3 months ago

    Tonix Pharmaceuticals Receives IND Clearance by U.S. FDA for TNX-102 SL in Agitation in Alzheimer’s Disease

    Tonix Pharmaceuticals Holding Corp. (TNXP) (Tonix), announced today that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application to support the initiation of a Phase 2, potential pivotal efficacy study of TNX-102 SL* 5.6 mg in patients with agitation in Alzheimer’s disease. TNX-102 SL, or Tonmya®# is a FDA-designated Breakthrough Therapy in Phase 3 development for the treatment of posttraumatic stress disorder (PTSD).

  • ACCESSWIRE4 months ago

    Blog Exposure - Tonix Pharma Announces 50% Enrolment in Tonmya® Study for PTSD

    Stock Monitor: China Pharma Holdings Post Earnings Reporting LONDON, UK / ACCESSWIRE / April 05, 2018 / Active-Investors.com has just released a free research report on Tonix Pharma Holding Corp. (NASDAQ: ...

  • Zacks Small Cap Research4 months ago

    TNXP: Phase 3 Trial in PTSD Nearing 50% Enrollment; Interim Analysis in 3Q18

    In 2017, Tonix (TNXP) announced the first patient was enrolled in the Phase 3 HONOR study of TNX-102 SL 5.6 mg for the treatment of posttraumatic stress disorder (PTSD, NCT03062540). The HONOR trial is a 12-week, multicenter, randomized, double blind, placebo controlled, fixed dose study of 5.6 mg TNX-102 SL (2 x 2.8 mg tablets) taken at bedtime. Approximately 550 subjects who have served in the military and meet a diagnosis of PTSD according to the Clinician-Administered PTSD Scale (CAPS-5) for DSM-5 are eligible to enroll.

  • Associated Press4 months ago

    Tonix reports 4Q loss

    The New York-based company said it had a loss of 71 cents per share. Losses, adjusted for non-recurring costs, were 67 cents per share. For the year, the company reported that its loss narrowed to $21.1 ...